ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Phone+1-617-4940400
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees459
OptionableOptionable
Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions
What is Ariad Pharmaceuticals' stock symbol?
Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."
How were Ariad Pharmaceuticals' earnings last quarter?
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) issued its earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.70. The pharmaceutical company earned $65.30 million during the quarter, compared to analysts' expectations of $60.64 million. Ariad Pharmaceuticals's quarterly revenue was up 133.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.28) EPS. View Ariad Pharmaceuticals' Earnings History.
Has Ariad Pharmaceuticals been receiving favorable news coverage?
News coverage about ARIA stock has been trending positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ariad Pharmaceuticals earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news stories about the pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days.
How do I buy shares of Ariad Pharmaceuticals?
Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ariad Pharmaceuticals' official website?
How can I contact Ariad Pharmaceuticals?
Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.
MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
